Adam D. Cohen, MD

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.